Gradual increases in dyslipidemia among male patients with human immunodeficiency virus primarily treated with tenofovir plus lamivudine plus efavirenz: a 3-year follow-up study

Dafeng Liu, Xingyi Zhang, Jun Kang, Fengjiao Gao, Yinsheng He, Shenghua HeResearch 2021 · DOI

Introduction

The advent of antiretroviral therapy (ART) has transitioned HIV infection from a terminal illness to a manageable chronic condition. However, long-term ART is frequently associated with metabolic complications, including dyslipidemia and altered purine metabolism. The regimen consisting of Tenofovir (TDF), Lamivudine (3TC), and Efavirenz (EFV) is a standard first-line treatment in many global health programs. While its efficacy in viral suppression is well-documented, its long-term impact on lipid profiles requires deeper investigation. This study evaluates the metabolic health of HIV-positive male patients over a 144-week period.

Methodology

This prospective cohort study followed 61 treatment-naive male patients at the Public and Health Clinical Center of Chengdu, China. Participants were categorized into three groups based on their baseline CD4+ T cell counts: <200, 200–350, and >350 cells/µl. All patients received the TDF+3TC+EFV regimen. Metabolic parameters, including Total Cholesterol (TC), Triglycerides (TG), LDL-c, HDL-c, and Uric Acid (UA), were monitored at baseline and at 12 subsequent intervals up to week 144. Statistical analysis utilized one-way ANOVA and multiple stepwise regression to identify predictors of metabolic shifts.

Results

Lipid Profile Evolution

The study observed a progressive increase in lipid levels over the 144-week follow-up. Total Cholesterol (TC) rose significantly from a baseline mean of 4.20 mmol/L to 4.67 mmol/L (P=0.001). Similarly, HDL-c levels showed a significant upward trend (P<0.001). While TG and LDL-c levels also increased, these changes did not reach statistical significance.

Trends in lipid parameters (TG, TC, LDL-c, and HDL-c) over 144 weeks of ART, stratified by baseline CD4+ T cell count.

Impact of Baseline Immune Status

Baseline CD4+ T cell counts were found to influence initial lipid levels. Patients with lower baseline CD4+ counts (<200 cells/µl) generally exhibited higher TG levels and lower TC, LDL-c, and HDL-c levels at the start of therapy. Over time, the prevalence of hypercholesterolemia increased from 24.59% to 50.00%, while the prevalence of low HDL-c decreased significantly from 36.07% to 7.14%.

Predictors of Metabolic Change

Regression analysis identified age, body weight, and the duration of follow-up as the primary drivers for increases in TC and TG. Interestingly, uric acid levels remained relatively stable and were more closely associated with viral load than with the duration of ART.

Discussion

The findings suggest that the "return to health" phenomenon—where lipid levels rise as the body recovers from HIV-induced wasting—may transition into a long-term risk for cardiovascular disease. The continuous rise in cholesterol levels beyond the initial recovery phase highlights the need for persistent monitoring. The correlation between body weight/fat and lipid levels underscores the importance of lifestyle management alongside pharmacological treatment.

Conclusion

While the TDF+3TC+EFV regimen is effective for viral control, it is associated with a gradual increase in dyslipidemia. Clinicians should prioritize long-term monitoring of lipid metabolism and consider early interventions to mitigate cardiovascular risks in patients undergoing prolonged ART.

Summary updated

Abstract

Abstract Introduction: Since the development of antiretroviral therapy (ART) with TDF plus 3TC plus EFV, this specific regimen has not been studied enough with long-term lipid and uric monitoring. Methods: A prospective follow-up cohort study was performed. Sixty-one treatment-naive male patients with HIV were divided into three groups based on their baseline CD4+ T cell count (26, 12, and 23 patients in the &lt;200, 200 to 350, and &gt;350 groups, respectively). The lipid and purine metabolism parameters of the patients over 144 weeks were analyzed. Result: TG, TC, LDL-c and HDL-c levels all gradually increased over 144 weeks, but the increases in TC levels and HDL-c levels were significant (P=0.001, 0.000, respectively). Moreover, the percentages of hypercholesterolemia, hyper LDL cholesterolemia and hypertriglyceridemia all showed gradual and nonsignificant increases; the percentage of low HDL cholesterolemia showed a gradual and significant decrease (P=0.0007). Furthermore, the lower the baseline CD4+ T lymphocyte counts were, the higher the TG levels were and the lower the TC, LDL-c and HDL-c levels were. However, only baseline LDL-c levels differed significantly between the three groups (P=0.0457). Although the UA level and the percentages of hyperuricemia gradually increased over 144 weeks, there was no significant difference between the different follow-up time point groups or between the three CD4+ T cell count groups (all P&gt;0.05). Further analyses revealed that the main factors contributing to lipid metabolism were age, anthropometric parameters and follow-up weeks, and virus load was the main factor contributing to uric acid levels. Conclusions: These findings provide a reference for clinicians to monitor lipid metabolism parameters closely during long-term ART with the TDF plus 3TC plus EFV regimen.
BibTeX
@inproceedings{liu2021gradual,
  author = {Dafeng Liu and Xingyi Zhang and Jun Kang and Fengjiao Gao and Yinsheng He and Shenghua He},
  title = {{Gradual increases in dyslipidemia among male patients with human immunodeficiency virus primarily treated with tenofovir plus lamivudine plus efavirenz: a 3-year follow-up study}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-238801/v1},
}
Figure